KCM
PRLD icon

Kynam Capital Management’s Prelude Therapeutics PRLD Stock Holding History

Kynam Capital Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9M Buy
2,415,087
+822,536
+52% +$3.58M 0.71% 21
2026
Q1 		$5.45M Buy
1,592,551
+803,684
+102% +$2.11M 0.34% 34
2025
Q4 		$2.29M Buy
+788,867
New +$1.33M 0.15% 37

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Kynam Capital Management's PRLD Position: Q2 2026 in Review

Kynam Capital Management increased its Prelude Therapeutics (PRLD) stake by 52% in Q2 2026, buying an estimated $3.58M and bringing the position to 2,415,087 shares worth $12.9M. The position accounts for 0.71% of the portfolio, ranked #21.

Kynam Capital Management first reported a position in PRLD in Q4 2025 and has held it in 3 quarters since. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Kynam Capital Management held 2,415,087 shares of Prelude Therapeutics worth $12.9M as of Q2 2026.
  • Kynam Capital Management bought 822,536 Prelude Therapeutics shares in Q2 2026, an estimated $3.58M.
  • Prelude Therapeutics made up 0.71% of Kynam Capital Management's portfolio in Q2 2026, its #21 holding.
  • Kynam Capital Management first reported a position in Prelude Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Kynam Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.